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Abstract: Skeletal muscle regeneration is ensured by satellite cells (SC), which upon activation undergo
self-renewal and myogenesis. The correct sequence of healing events may be offset by inflammatory
and/or fibrotic factors able to promote fibrosis and consequent muscle wasting. Angiotensin-II (Ang)
is an effector peptide of the renin angiotensin system (RAS), of which the direct role in human SCs
(hSCs) is still controversial. Based on the hypertrophic and fibrogenic effects of Ang via transient
receptor potential canonical (TRPC) channels in cardiac and renal tissues, we hypothesized a similar
axis in hSCs. Toward this aim, we demonstrated that hSCs respond to acute Ang stimulation,
dose-dependently enhancing p-mTOR, p-AKT, p-ERK1/2 and p-P38. Additionally, sub-acute Ang
conditioning increased cell size and promoted trans-differentiation into myofibroblasts. To provide
a mechanistic hypothesis on TRPC channel involvement in the processes, we proved that TRPC
channels mediate a basal calcium entry into hSCs that is stimulated by acute Ang and strongly
amplified by sub-chronic Ang conditioning. Altogether, these findings demonstrate that Ang induces
a fate shift of hSCs into myofibroblasts and provide a basis to support a benefit of RAS and TRPC
channel blockade to oppose muscle fibrosis.
Keywords: satellite cells; angiotensin; TRPC channels; Ca2+ signaling; myofibroblast; myogenesis;
hypertrophy; skeletal muscle
1. Introduction
Healthy skeletal muscle has a powerful regenerative potential that enables physiological growth
and efficient repair following insults. Conditions able to impair this capacity have a negative prognostic
impact on disability by promoting skeletal muscle frailty [1].
Muscle regeneration is ensured by resident stem cells, i.e., satellite cells (SCs), which at rest lie
quiescently in niches adherent to myofibrils. Following injuries, SCs are prompted to activate and
migrate into the damaged area, eventually entering into symmetric and asymmetric divisions aimed to
replenish the SC pool and accomplish regenerative myogenesis [1]. SC activation and differentiation
are finely orchestrated events, largely dependent on niche composition; in this respect, enrichment of
the local microenvironment with inflammatory and/or fibrotic factors may drive SCs toward incorrect
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healing and consequent muscle wasting [2]. The identification of factors and mechanisms inducing
muscle fibrosis may help uncover innovative drug targets potentially useful to prevent or limit
muscle deterioration.
Angiotensin II (Ang) is one of the effector peptides of the renin angiotensin system (RAS), of which
the role in skeletal muscle, and particularly on SCs, remains controversial. Compelling studies have
demonstrated detrimental effects of Ang on mouse SC growth and activation [2,3], while others are
suggestive of positive effects of Ang on muscle healing via chemiotaxis of C2C12 myoblasts [4,5].
Interestingly, Yoshida et al. [6] revealed a positive role of Ang type-2 (AT2) receptors in skeletal muscle
regeneration. Regardless of the prominent effects, evidence in cardiovascular patients indicates that
long-term therapies with angiotensin-converting enzyme inhibitors (ACEIs) or Ang type-1 (AT1)
receptor antagonists (ARBs) [7,8] slow down the progressive decline of muscle mass and contractile
performance, often associated with cardiac and renal hypertrophy and fibrosis [9–17]. However, it is
not clear whether ACEIs or ARBs ameliorate muscle wasting through the benefits exerted at cardiac
and renal levels or whether they also directly enhance muscle regenerative capacity and/or its resistance
to injuries. Of note, there is limited knowledge on the effects of Ang and ARBs on human SCs (hSCs),
a setting in which the presence of a complete RAS has not been documented in detail [18,19].
In cardiac and renal pathologies, over-activation of RAS conveys distinct pathogenic signals
responsible for inflammation, hypertrophy, and fibrosis [7,8,20]. Some of these effects are secondary
to Ang receptor activation and subsequent stimulation of the canonical transient receptor potential
(TRPC) channels [21–27], evidence that attributes a distinctive role to the Ang-TRPC channel axis in
cardio-renal hypertrophy and fibrosis. TRPC channels comprise seven different isoforms (TRPC1–7)
co-assembling to form non-selective, Ca2+-permeable tetramers [28]. They underlie the store-operated
channels, being activated by depletion of intracellular Ca2+ stores; additionally, they can be activated
by mechanical stretch and by stimulation of Gq-coupled receptors, including Ang receptors [21–27].
Since Ca2+ dynamics regulates skeletal muscle development, homeostasis, and regeneration [29,30],
we hypothesized a possible role of Ang-TRPC channel axis on hSC fate determination toward
non-myogenic lineage. To test this hypothesis, in this study, we provided evidence that Ang promotes
hypertrophy and myofibroblast trans-differentiation of hSCs and that this fate decision is associated
to Ca2+ entry via activation of TRPC channels. In parallel, to elucidate the mechanisms and provide
a basis to support clinical benefits of RAS blockade in muscle fibrosis and wasting, the effects of Ang
were evaluated in the presence of irbesartan (Irb), an AT1 receptor antagonist.
2. Results
2.1. Characterization of hSC Phenotype
Primary hSCs undergo quick phenotype modifications in culture that may potentially interfere
with experimental findings. To overcome this limitation, we first identified the passage interval
of cell phenotype stability by immunofluorescence detection of key myogenic markers. In our
experimental conditions, hSCs at passages 1–3 expressed Paired box protein 7 (PAX7, Figure 1a),
a transcription factor present in quiescent and activated SCs that is downregulated during myogenic
differentiation [31]. Cells also stained positive for myogenic factor 5 (MYF5) and myogenic factor 3
(MYOD), two transcription factors of myogenic lineage [32]; at the same time, they were negative for
the transcription factor myogenin and the contractile protein myosin heavy chain (MHC), indicating
the absence of myogenic differentiation. While Pax7, Myf5, and MyoD were present in almost all
cells at passages 1–3, Myogenin and myosin heavy chain (MHC) were rarely observable (Figure 1b).
This expression pattern, typical of activated hSCs appeared stable throughout passages 1–3; thereafter,
it spontaneously changed over subsequent passages, thus limiting culture use to passages 1–3 for the
following experiments.
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Figure 1. Phenotype of cultured human satellite cells (hSCs): immunolabelling (a) and percentage of
positive cells (b) for Paired box protein 7 (PAX7), myogenic factor 5 (MYF5), myogenic factor 3 (MYOD),
myogenin, and myosin heavy chain (MHC) in cultured hSCs at passage 3. Target proteins are depicted
in red, and cell nuclei are in blue (DAPI). The image magnification is 20×.
2.2. Activated hSCs Express a Functional RAS Protein Panel
The presence of RAS protein in activated hSCs was investigated by immunofluorescence
and western blot analysis of protein extracts. All individual proteins of the conventional and
non-conventional RAS were expressed (Figure 2a,b); in particular, staining revealed that almost all
cells were positive for AT1, AT2, and MAS receptors, which showed cytosolic and plasma membrane
localization. Densitometric analysis of immunoblotting evidenced a prominent expression of MAS and
AT1 over AT2 receptors in total protein extracts (Figure 2b). This expression pattern was qualitatively
similar to that retrieved in whole skeletal muscle extracts (Figure S1a,b).
Figure 2. Expression of renin angiotensin system (RAS) proteins in activated hSCs: (a) immunolabelling
of type-1 (AT1), type-2 (AT2), and MAS receptors, and angiotensin-converting enzymes 1 (ACE1) and 2
(ACE2) in cultured hSCs at passage 3. Target proteins are depicted in red, cell nuclei are in blue (DAPI).
The image magnification is 20×; (b) immunoblotting (top) and densitometric analysis (bottom) of AT1,
AT2, and MAS receptors, and ACE1 and ACE2 in protein extracts of hSCs at passage 3. The histogram
shows the ratios (mean ± standard error of the mean (SEM), n = 3) between the expression levels of
target proteins and GAPDH.
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Type-1 and -2 angiotensin-converting enzymes (ACE1 and ACE2, respectively) were also expressed
at a protein level in activated hSCs, displaying comparable amounts (Figure 2a,b). This suggests that
activated hSCs retain all the enzymatic requirements necessary to synthesize Ang and possibly other
related peptides.
To assess the function of RAS protein in activated hSCs, we exposed cells to increasing
concentrations of Ang (1, 10, and 100 nM) or standard growing medium (CTR) for 15 min and
analyzed the phosphorylation levels of intracellular protein kinases that are typically enhanced by Ang
in other cells, namely p-mTOR, p-AKT, p-ERK1/2, and p-P38. Results (Figure 3a–e) showed that Ang
induced a concentration-dependent increase of the phosphorylation levels of each individual protein
kinases, which were significant at 100 nM Ang compared to CTR (p-mTOR, p-AKT, and p-ERK1/2:
* p < 0.05 vs. CTR; p-P38: ** p < 0.01 vs. CTR). For all proteins, enhancement of phosphorylation was
similarly prevented by 1µM Irb, suggesting the involvement of AT1 receptor in these signals.
Figure 3. Signaling cascade stimulated by acute Ang in hSCs: (a) representative immunoblotting
of p-mTOR, p-AKT, p-ERK1/2, p-P38, and GADPH detected in protein extracts of cultured hSCs
stimulated or not (CTR) with 1–100 nM angiotensin II (Ang) for 15 min with/without 1 µM irbesartan
(Irb); densitometric analysis of p-mTOR (b), p-AKT (c), p-ERK1/2 (d), and p-P38 (e) levels, reported as
ratios between the levels of the target protein and GAPDH. Results are presented as mean ± SEM of the
three gels. * p < 0.05 vs. CTR, ** p < 0.01 vs. CTR.
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2.3. Sub-Chronic Conditioning of Activated hSCs with Ang Leads to Hypertrophy and Myofibroblast
Trans-Differentiation Without Modification of Cell Viability
Since Ang is reported to stimulate hypertrophy and fibrosis in renal and cardiac cells [20],
we explored whether similar effects were induced in activated hSCs. Cell conditioning with 100 nM
Ang for 24 h resulted in increased cell cross-sectional areas, which were significantly larger compared
to cells grown in a standard medium (M, Figure 4a,b, *** p < 0.001 vs. M). The effect was completely
prevented by Irb, indicating that AT1 receptors were responsible for the hypertrophic response. Irb
alone did not modify cell sizes, of which values were almost equal in cells grown in the M.
Figure 4. Cont.
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Figure 4. Effect of sub-chronic conditioning with Ang on hSC-size and myofibroblast markers:
(a) Representative photomicrographs of cells labelled with Alexa Fluor (red) and DAPI (blue); (b)
Values of cell cross-sectional areas (mean ± SEM) evaluated blind by two researchers using the drawing
function of ImageJ software; immunolabelling and relative quantifications of α-smooth muscle actin
(c,d), transgelin-2 (e,f), and β-catenin (g,h). Target proteins are stained in red, cell nuclei are in blue
(DAPI). Quantifications of protein expression were performed blind by two researchers. All image
magnifications are 20×; (i) immunoblotting (top) of myostatin detected in protein extracts of cultured
hSCs and densitometric quantification (bottom). * p < 0.05, ** p < 0.01 and *** p < 0.001. In this
experiment, hSCs were cultured for 24 h in a standard medium (M) or M supplemented with 100 nM
Ang (M + Ang), or 1 µM irbesartan (M + Irb) or 1 µM Irb plus 100 nM Ang (M + Irb + Ang).
To assess whether sub-chroning conditioning with Ang also promoted a fate switch of hSCs
toward myofibroblasts, we analyzed the expression of myofibroblast markers, namelyα-smooth muscle
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actin (α-SMA) and transgelin-2. After 24 h conditioning with Ang, both markers were significantly
increased compared to those in cells grown in the M (Figure 4c–f, α-SMA: *** p < 0.001 vs. M;
transgelin-2: * p < 0.05 vs. M). Interestingly, expression levels remained high after cell conditioning
with Ang plus Irb, suggesting that, differently from hypertrophy, myofibroblast trans-differentiation
was independent of AT1 receptors. Similarly, β-catenin protein was increased in Ang- and Ang +
Irb-conditioned cells (Figure 4g–h, ** p < 0.01 vs. M), further indicating an AT1-independent pathway
leads to myofibroblast trans-differentiation.
Finally, we also analyzed the expression of myostatin, a potent pro-inflammatory and fibrogenic
peptide acting as an inhibitor of myogenic differentiation. Surprisingly, blot analysis showed that
myostatin levels were similar in the M, and Ang- and Irb-conditioned cells, while they significantly
increased in cells conditioned with Ang plus Irb (Figure 4i; ** p < 0.01 vs. M). This further reinforced the
hypothesis of an AT1 receptor-independent pathway supporting myofibroblast trans-differentiation.
We also assessed whether hypertrophy and trans-differentiation induced by Ang were associated
to modifications of hSC viability. MTT oxidation values in all conditions expressed as mean ± standard
deviation of the mean were similar: 0.090 ± 0.012 in cells grown in the M at t = 0 h, 0.167 ± 0.015 in
cells grown in M for 24 h, 0.201 ± 0.005 in cells grown in Irb for 24 h, 0.143 ± 0.0085 in cells grown in
Ang for 24 h, and 0.171 ± 0.01 in cells grown in Ang + Irb for 24 h. This finding excluded any negative
effect of conditioning on cell viability.
2.4. Sub-Chronic Conditioning of Activated hSC with Ang Enhances TRPC Channel Function and Modifies
Expression Patterns of AT Receptors
In order to provide a mechanistic hypothesis on the effects induced by Ang conditioning in
activated hSCs, we assessed whether, similarly to renal and cardiac cells, a functional link between
Ang and TRPC channels is effective in our model.
We first determined the expression panel of TRPC channels in activated hSCs by quantitative
RT-PCR, immunofluorescence staining, and western blotting. Results revealed that TRPC1, 3, 4, 6
isoforms, but not TRPC5, 7, are detectable as mRNAs (Figure 5a) and as proteins in most cells (Figure 5b)
and total protein extract (Figure S3).
Thereafter, we performed fluorescence calcium imaging in cultured hSCs and found that TRPC
channels co-assembled into functional pores exhibiting properties consistent with those described
for typical TRPC channels [25]. In detail, in cells grown for 24 h in the M (Figure 5c), depletion of
intracellular Ca2+ stores by CPA (Veh + CPA), and switch from 0 to 1.8 mM external Ca2+ elicited
a transient increase of intracellular fluorescence (Figure 5c, trace c1, and column d1), as expected for
Ca2+ entry through the plasmalemma. A major component of it, accounting for nearly two-thirds of
the total amount, was significantly inhibited by 5 µM SKF96365 (SKF, Figure 5c, trace c2, column d2, *
p < 0.05 d2 vs. d1), a non-selective TRPC channel blocker. The residual SKF-insensitive component
was not further investigated in the study.
Figure 5. Cont.
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Figure 5. Functional coupling between Ang and TRPC channels on hSCs: (a) mRNA expression of
TRPC1–7 channels in hSCs at passage 3; (b) immunolabelling of TRPC1, 3, 4, 6 channels in hSCs.
Channel proteins are stained in red, and nuclei are in blue (DAPI). All image magnifications are 20X; (c)
experimental scheme (top) used for 24 h conditioning of hSCs prior to fluorescence calcium imaging.
Culture conditions were: M supplemented with 100 nM Ang (M + Ang), 100 nM Ang plus 1µM
irbesartan (M + Ang + Irb), or 100 nM Ang plus 100 nM PD123319 (M + Ang + PD). The experimental
protocol to perform fluorescence calcium imaging used a vehicle solution (Veh) supplemented with 5
µM cyclopentyladenosine (Veh + CPA) and 0 or 1.8 mM CaCl2 to stimulate a transient intracellular
Ca2+ entry (trace c1). The histogram (bottom) shows mean peak values (±standard error) of Ca2+
transients measured in cells cultured in the M for 24 h (column d1), exposed to acute 5 µM SKF (d2,
trace c2,), 100 nM Ang (d3, trace c3,), Ang plus SKF (d4, trace c4), Ang plus Irb (d5, trace c5), and Ang
plus PD (d6, trace c6). Ca2+ transients measured in cells conditioned for 24 h in M + Ang (top scheme)
are represented by trace c7 and column d7, and by trace c8 and column d8 after acute stimulation by
100 nM Ang. Similar measurements were performed in: cells conditioned for 24 h in M + Ang + Irb
(top scheme) without/with acute stimulation by Ang (trace c9, column d9/trace c10, column d10); cells
conditioned for 24 h in M + Ang + PD (top scheme) without/with acute stimulation by Ang (trace c11,
column d11/trace c12, column d12). * p < 0.05, *** p < 0.001.
The SKF-sensitive Ca2+-transient identified in our cell system was further characterized with
respect to the effect of Ang. Acute exposure to 100 nM Ang for 10 min evidenced a positive modulation
of TRPC channels (Figure 5c), trace c3 and column d3, *** p < 0.001 d3 vs. d1), indicating that these
channels in hSCs share a typical modulatory signal identified in other cell types [25]. The enhancement
was completely inhibited by SKF (Figure 5c), trace c4 and column d4, ***p < 0.001 d4 vs. d3), further
confirming the involvement of TRPC channels in basal and Ang-stimulated Ca2+ entry into hSCs.
The stimulatory effect of Ang was prevented by 1 µM Irb and 1 µM PD123319 (PD, Figure 5c),
traces c5 and c6, columns d5 and d6, *** p < 0.001 vs. d3), selective antagonists of AT1 and AT2
receptors, respectively.
Next, to test whether subchronic conditioning with Ang leading to hypertrophy and myofibroblast
trans-differentiation of hSC was associated to modifications of TRPC channel function, we repeated
fluorescence calcium imaging using the same protocol described above in cells grown for 24 h in the
M supplemented with 100 nM Ang, or Ang plus Irb, or Ang plus PD (Figure 5c), M + Ang, M + Irb,
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and M + PD). Results showed that in cells conditioned with Ang for 24 h, basal Ca2+ entry elicited
by switching external Ca2+ from 0 to 1.8 mM was still evident and significantly higher compared to
that measured in cells grown in the M for 24 h (Figure 5c), trace c7 and column d7, *** p < 0.001 vs
column d1). Moreover, TRPC channels in Ang-conditioned cells still were stimulated by acute Ang, as
demonstrated by the enhanced fluorescence (Figure 5c), trace c8 and column d8, * p < 0.05 vs column
d7). Of note, the stimulatory effect of acute Ang was significantly larger compared to that induced in
cells grown in the M for 24 h (Figure 5c), trace c8 and column d8, *** p < 0.001 vs. d3). Additionally,
cells conditioned with Ang plus Irb or Ang plus PD for 24 h showed similar fluorescence levels that
did not respond to acute Ang (Figure 5c), traces c9–c12 and columns d9–d12). Thus, TRPC channel
function in hSCs is amplified by sub-chronic conditioning with Ang for 24 h both in the basal- and
Ang-stimulated component.
Finally, we assessed whether cell conditioning with Ang for 24 h modified the expression panel of
AT receptors. Western blot analysis (Figure 6a,b) showed that AT1 receptors were not modified by
24 h conditioning with Ang or Irb alone, while they were significantly downregulated by Ang plus
Irb compared to cells grown in M (** p < 0.01 vs. M). Differently, AT2 receptors were significantly
upregulated by Ang conditioning (* p < 0.05 vs. M) and the enhancement was not prevented by Irb
(* p < 0.05 vs. M).
Figure 6. Effect of sub-chronic Ang conditioning of hSCs on expression of AT1 and AT2 receptors:
(a) Representative immunoblotting (top) and densitometry analysis (bottom) of AT1 receptors expressed
in hSCs cultured for 24 h in the M supplemented or not with 100 nM Ang, 1 µM Irb, or Ang plus
Irb (Ang + Irb); (b) representative immunoblotting (top) and densitometry analysis (bottom) of AT2
receptors expressed in hSCs cultured as in (a). Densitometry analysis is reported as ratios between
the levels of the target protein and GAPDH. Results are presented as mean ± SEM of the three gels.
* p < 0.05 vs. M, ** p < 0.01 vs. M.
3. Discussion
In healthy muscle, activated SCs balance myogenic differentiation and self-renewal to
simultaneously sustain regeneration and replenish progenitor pools [1]. Latter events are major
determinants to preserving long-term regenerative ability and effectively respond to growth stimuli.
Any conditions able to exhaust SC pools, such as aging, cardiovascular diseases, and muscle dystrophies,
may facilitate muscle wasting. Interestingly, all these conditions exhibit various degrees of RAS
over-activation, elevated levels of systemic and local Ang, and muscle fibrosis [20].
Despite Ang is recognized as a potent fibrogenic factor in the muscle [2], little information
is available on hSCs as cell mediators of fibrosis [33]. The main findings provided in this study
demonstrate that Ang acts directly on activated hSCs, inducing hypertrophy and myofibroblast
trans-differentiation in vitro (Figure 4), two crucial transitional states leading cells to enter the fibrotic
program. This reprogramming switch integrates hSCs into the family of the direct cell sources of
myofibroblasts in vitro and represents a novel finding for both the effects of Ang on myogenic cells
and the cell sources of myofibroblasts [34]. Whether a similar reprogramming process occurs in vivo is
Int. J. Mol. Sci. 2019, 20, 4912 10 of 17
currently unknown; indeed, most studies in muscle have documented the formation of myofibroblasts
through differentiation of fibroblasts, reprogramming of bone marrow-derived cells, and mesenchymal
transition of epithelial cells, disregarding the possibility of a direct myofibroblast trans-differentiation
of SCs stimulated by Ang. Occurrence of such trans-differentiation in vivo would unveil a different
cell source of fibrosis induced by locally elevated Ang, which could be relevant to identification of
novel targetable mechanisms of muscle wasting.
Our data demonstrated that intracellular signaling elicited by Ang in activated hSCs, namely
hyper-phosphorylation of p-mTOR, p-ERK1/2, p-P38, and p-AKT (Figure 3), resembles that involved
in the hypertrophic response of cardiac cells by stimulation of Ang-AT1 [20]. This suggested that the
hypertrophic effect of Ang in hSCs is likely attributable to the same AT1-signaling documented in
cardiac cells. Conversely, our findings also showed that trans-differentiation of hSC into myofibroblasts
is independent of AT1 receptors, as demonstrated by the inability of Irb to reduce fibrotic markers
induced by cell conditioning with Ang (Figure 4c–i). This result led us to consider that other receptors
expressed in our system, i.e., AT2 or MAS receptors, may play a role in the fibrogenic process.
This possibility is not obvious and apparently opposes the anti-fibrotic role of AT2 and MAS receptors
reported for skeletal muscle, heart, and kidney [20]. On the other hand, our experimental evidence
is in line with data demonstrating a pro-fibrotic role of AT2 receptors when overexpressed in the
heart [35–37]; notably, a similar expression pattern of Ang receptors is present in hSCs conditioned
with Ang for 24 h, where AT2 receptors are increased, while AT1 are unchanged (Figure 6a,b).
A different explanation might attribute myofibroblast trans-differentiation induced by Ang to
Ang-related peptides, i.e., Ang-(1–7) and Ang-(1–9), possibly formed in our culture system by the
cleaving activity of ACE2. This enzyme is expressed at a protein level in hSCs (Figure 2); however,
we did not explore the effective production of the above peptides at this time and it remains as
an intriguing hypothesis to be tested in further work. Finally, another possibility is that Ang or
Ang-(1–7) behave as biased agonists of AT1 receptors in hSCs [38], leading to the recruitment of
β-arrestins and triggering of ERK1/2 phosphorylation; interestingly, p-ERK1/2 levels are enhanced
in hSCs conditioned with Ang (Figure 3), which might thus make a contribution of this signal in
our system.
Altogether, each of the above-mentioned hypotheses are likely to occur in our culture system; however,
further investigations are necessary to clarify the major mechanism(s) occurring in our conditions.
Based on data supporting a role of Ang-TRPC channel axis in cardiac and renal fibrosis [23,39,40],
in this study, we explored whether a similar role could be hypothesized in our setting. Indeed, we found
that hSCs express TRPC1, 3, 4, 6 channel isoforms, which co-assembled into functional tetramers
passing Ca2+ ions into hSCs. The Ca2+ flux was analyzed by fluorescence imaging and showed three
peculiar properties, namely activation by depletion of internal Ca2+ stores, sensitivity to a selective
blocker, and positive modulation by Ang (Figure 5c), which jointly are attributable to typical TRPC
channels [25,41]. Interestingly, our findings demonstrated that TRPC channels in hSCs are stimulated
by both AT1 and AT2 receptors. While the stimulatory effect by AT1 receptors is widely documented
in the literature, that of AT2 receptors has only been reported in renal podocytes [42]. In these cells,
the positive modulation exerted by AT1 and AT2 receptors on TRPC channels is part of a redundant
pathway necessary to guarantee podocyte-specific functions in the kidney; it is possible that in hSCs
such a double regulatory pathway is also required for basal function(s) in the muscle, as suggested by
impaired myogenic differentiation in TRPC3 or STIM1/ORAI1 ablation models [30,43].
We also provided evidence that Ang sub-chronic conditioning of hSCs upregulates TRPC channel
function, thereby amplifying basal and Ang-stimulated Ca2+ entry inside cells. This gain of function of
TRPC channels is likely dependent on the increased expression of AT2 receptors (Figure 6) in hSCs
conditioned with Ang, an effect that may be sufficient to enhance the positive coupling of Ang with
TRPC channels. However, we cannot exclude other possible mechanisms, such as transcriptional
upregulation of TRPC channels induced by Ang conditioning that might concur to enhance Ang-TRPC
channel coupling. Regardless of the mechanism leading to enhance the Ang-TRPC channel axis in hSCs,
Int. J. Mol. Sci. 2019, 20, 4912 11 of 17
we hypothesized that the amplified response of intracellular Ca2+ following these modifications may
contribute to shaping the myogenic fate of hSCs, promoting their hypertrophy, and switching them
toward myofibroblasts. This hypothesis is in line with experimental findings on fibrotic transformation
of mouse C2C12 myoblasts induced by Ang, a transformation associated with enhanced intracellular
Ca2+ levels, although this effect was not attributed to TRPC channels [44]. It is worth noting that
many studies have documented that sustained intracellular Ca2+ levels in myogenic cells exert distinct
long-term function through activation of downstream Ca2+-dependent signals, including nuclear factors
of activated T-cells (NFAT), mitogen-activated protein (MAP) kinase, and ERK1/2 [30]. Importantly,
signals arising from activation of the Ang-TRPC channel axis were proven to be key effectors of fibrosis
in cardiac and renal cells [21–27], suggesting that this axis might represent a widespread promoter of
fibrosis in tissues sensitive to abnormal levels of Ang.
In conclusion, our study provides evidence that Ang drives hSCs toward hypertrophy and
myofibroblast differentiation, advancing current knowledge on RAS signaling on myogenic cells.
Effects induced by Ang in hSCs are associated to basal- and Ang-stimulated TRPC channel gains
of function, which we propose as possible molecular mediators of the effect of Ang. Altogether,
this information represents a basis to investigate whether a similar reprogramming pathway of hSCs
occurs in vivo in conditions of RAS over-activation. Overall, our findings support a potential benefit
of RAS and/or TRPC channel blockers in muscle wasting and fibrosis.
4. Materials and Methods
4.1. hSC Preparation
The study was conducted in accordance with the Declaration of Helsinki 1975, revised in 2013.
The protocol was approved by the Ethics Committees of Meyer Children’s Hospital, Florence, Italy
(project protocol: 105/2016, date of approval: 28 June 2016), and of Azienda Ospedaliero-Universitaria
Careggi, Florence, Italy (project protocol: 2015/0009082, date of approval: 25 March 2015). All subjects
gave their informed consent for inclusion before they participated in the study.
Specimens from pectoralis muscle were obtained from waste skeletal muscle resection of patients
undergoing corrective surgery at Meyer Children’s Hospital (Florence, Italy) using a protocol approved
by the local ethics committee. Specimens were maintained in an appropriate cold transport solution
(see Section 4.7) and cleaned of adipose tissue. Digestion was performed with Type 1 collagenase in
high glucose DMEM (2.2 mg/mL, Sigma-Aldrich, Schnelldorf, Germany) at 37 ◦C for 30 min, in 5%
CO2 and 90% humidified air. Digested fragments were then transferred to Promocell Growth Medium
(Promocell Gmbh, Heidelberg, Germany) and gently pipetted until complete cell dispersion. Thereafter,
cells were pre-plated in 6-well plates (5 × 102 cells/well) for 1 h, at 37 ◦C, in atmosphere 5% CO2
and 90% humidified air, and non-adherent fibers were removed and plated on multi-wells coated
with matrigel (Sigma-Aldrich, Schnelldorf, Germany). In this condition, fibers were maintained for
1–2 weeks, with the medium changed every 2 days, and evidenced SC proliferation within 2 weeks.
Proliferating SCs were then cultured at 60%–70% confluence, detached by standard trypsinization and
diluted 1:3. All subsequent experiments were performed at passages 1–3.
4.2. Immunofluorescence
hSCs were seeded in a 12-well plate (5 × 102 cells/well) and maintained in a standard growing
medium (CTR), supplemented or not with Ang (0.1, 1, or 100 nM), Irb (1 µM), or Ang (100 nM) and Irb
(1 µM). The durations for drug exposure were 15 min and 24 h in acute and sub-chronic treatments,
respectively. Before staining, hSCs were washed with PBS, fixed with 4% paraformaldehyde in PBS for
15 min at room temperature, washed again, and permeabilized with 0.3% TritonX100 in PBS for 10 min.
Thereafter, cells were treated for 10 min at room temperature with PBS containing 1% BSA to avoid
non-specific binding of antibodies. Primary antibodies (Table 1), diluted in PBS containing 0.1% Tween
and 1% BSA, were incubated overnight at 4 ◦C; after washing with PBS, treatment with the secondary
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antibody (Table 1, diluted 1:150) was performed for 2 h at room temperature. Finally, hSCs were treated
with 0.1% Tween and 4′,6-diamidin-2 phenylindole (DAPI; 0.005 µg/mL PBS and images viewed
by a low-power objective (20X magnificationand a rhodamine filter. Images were digitized using
a video image obtained by a CCD camera (Diagnostic Instruments Inc., Sterling Heights, MI, USA),
controlled by a specific software (InCyt Im1™; Intracellular Imaging Inc., Cincinnati, OH, USA),
and analyzed using ImageJ 1.33 analysis software. For each target, 20 fields were taken randomly.
All reagents for immunofluorescence, unless otherwise specified, were purchases from Sigma-Aldrich
(Schnelldorf, Germany).
Table 1. List of primary and secondary antibodies used for immunofluorescence (IF) and western blot
(WB) analysis.
Antibodies Dilution Supplier
Anti-ACE1 1:50 (IF) Santa Cruz Biotechnology, Heidelberg, Germany
Anti-ACE2 1:50 (IF) Santa Cruz Biotechnology, Heidelberg, Germany
Anti-ATR1 1:100 (IF)1:500 (WB) Alomon Labs, Jerusalem, Israel
Anti-ATR2 1:200 (WB) Alomon Labs, Jerusalem, Israel
Anti-GAPDH 1:7000 (WB) Merk-Millipore, Darmstadt, Germany
Anti-Myf5 1:100 (IF) Santa Cruz Biotechnology, Heidelberg, Germany
Anti-MyoD 1: 100 (IF) Santa Cruz Biotechnology, Heidelberg, Germany
Anti-myogenin 1:100 (IF) Developmental Studies Hybridoma Bank, Iowa City, Iowa,United States of America
Anti-myostatin 1:300 (WB) Biorbyt Explore, Cambridge, United Kingdom
Anti-myosin heavy chain 1:100 (IF) BD Pharmingen, San Jose, California, United States of America
Anti-Pax7 1:100 (IF) Developmental Studies Hybridoma Bank, Iowa City, Iowa,United States of America
Anti-p-AKT 1:1000 (WB) Cell Signaling Technology, Leiden, The Netherlands
Anti-p-ERK1/2 (Thr202/Tyr204) 1:1000 (WB) Cell Signaling Technology, Leiden, The Netherlands
Anti-p-mTOR 1:1000 (WB) Cell Signaling Technology, Leiden, The Netherlands
Anti-p-P38 1: 400 (WB) Cell Signaling Technology, Leiden, The Netherlands
Anti-TRPC1 1:100 (IF)1:200 (WB) Alomon Labs, Jerusalem, Israel
Anti-TRPC3 1:100 (IF)1:200 (WB) Alomon Labs, Jerusalem, Israel
Anti-TRPC4 1:100 (IF)1:200 (WB) Alomon Labs, Jerusalem, Israel
Anti-TRPC5 1:100 (IF)1:200 (WB) Alomon Labs, Jerusalem, Israel
Anti-TRPC7 1:100 (IF)1:200(WB) Alomon Labs, Jerusalem, Israel
Anti-Mas receptor 1:100 (IF) Santa Cruz Biotech, Heidelberg, Germany
Anti-smooth muscle actin 1:100 (IF) Dako, Santa Clara, California, United States of America
Anti-catenin 1:1000 (IF) BD Pharmingen, San Jose, California, United States of America
Anti-transgelin 2 1:100 (IF) Everest Biotech, Upper Heyford, United Kingdom
Anti-vimentin 1:100 (IF) Santa Cruz Biotech, Heidelberg, Germany
Anti-rabbit IgG-Alexa Fluor 594 1:500 (IF) Thermo Fisher scientific, Bengaluru, India
Anti-chicken IgG-Alexa Fluor 647 1:500 (IF) Thermo Fisher scientific, Bengaluru, India
4.3. Western Blot Analysis
Protein lysates were recovered from plated hSCs using lysis buffer and analyzed by the BCA
method (Pierce). Twenty micrograms of proteins were separated on 4%–20% SDS-PAGE (Thermo
Fisher scientific, Life Technologies, Carlsbad, CA, USA) and transferred into PVDF membranes
(60 min at 398 mA) using standard procedures. Blots were incubated overnight at 4 ◦C with a specific
antibody (Table 1). Primary antibodies were diluted in PBS containing 1% BSA or 5% non-fat dry milk
and 0.05% Tween. The antigen–antibody complexes were visualized using appropriate secondary
antibodies (diluted 1:10000 in PBS containing 1% albumin or 5% non-fat dry milk and 0.05% Tween)
and left for 1 h at room temperature. Blots were then extensively washed with PBS containing 0.1%
Tween and developed using an enhanced chemiluminescence detection system (Pierce, Rodano, Italy).
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Exposure and developing time were standardized for all blots. Densitometric analysis of scanned
images was performed on a Macintosh iMac computer using the public domain NIH Image program.
Results represent the mean± SEM of different gels and are expressed as arbitrary units (AUs), consisting
of the ratio between the levels of target protein and GAPDH. All reagents, unless otherwise specified,
were purchases from Sigma-Aldrich (Schnelldorf, Germany).
4.4. Quantitative PCR Analysis
Total RNA was obtained from cultured hSCs using the Macherey Nagel Nucleo spin RNA
kit (MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany). One microgram of total RNA
was reversed transcribed using iScript™ Select cDNA Synthesis Kit (Bio-Rad Laboratories, Bio-Rad
Laboratories, Segrate (MI), Italy), according to the manufacturer’s instructions. Gene primers were
obtained from Bio-Rad Laboratories Bio-Rad Laboratories, Segrate (MI), Italy: TRPC1 (unique
assay ID: qHsaCED0045239), TRPC3 (unique assay ID: qHsaCID0018563), TRPC4 (unique assay
ID: qHsaCED0036540), TRPC5 (unique assay ID: qHsaCID0017182), TRPC6 (unique assay ID:
qHsaCED0034676), TRPC7 (unique assay ID: qHsaCID0009550), and GADPH (unique assay ID:
qAthCED0035454). Real-time PCR reaction was carried out in 10 µL volumes in 96-well plates (Applied
Biosystems, London, UK) using 1 µL of cDNA mixed with 3 µL nuclease-free water, 1 µL of sense
and antisense primers (10 µM), and 5 µL of Ssoadvanced Universal SYBR Green Supermix (Bio-Rad
Laboratories, Segrate (MI), Italy). Reaction was performed using the following thermocycler (7900HT
Fast Real-Time PCR System (Applied Biosystems, London, UK) program for all genes: 95 ◦C for 1
min followed by 40 cycles at 95 ◦C for 15 s, at 60 ◦C for 60 s, and at 72 ◦C for 45 s. Each experiment
was repeated in triplicate, and quantitative analysis was performed with the ∆CT method. GAPDH
was used for normalization. As a positive control, a homogenized sample from human kidney was
used (Figure S2).
4.5. Assessment of Cell Viability/Growth
hSCs were plated at a density of 500 cells/plate in 96-well plates and cultured in standard
conditions for 24 h and then in a starving medium (i.e., DMEM with 0.01% BSA) for additional 24 h.
Thereafter, cells were exposed to a complete growing medium (CTR) with or without Ang (100 nM)
and Irb (1 µM). Cell growth was evaluated 24 h later by measuring MTT oxidation (Sigma-Aldrich,
Schnelldorf, Germany).
4.6. TRPC-Mediated Ca2+ Imaging
Adherent hSCs were loaded with 5–10 µM Fluo-4 AM (Molecular Probes, Eugene, OR, USA) and
placed in a heated (36 ± 1 ◦C) stage of an inverted microscope. Experimental protocols were similar to
those described earlier [25]. Briefly, cells were perfused for 10–15 min with a Ca2+-free normal Tyrode’s
solution (see Section 4.7) containing cyclopiazonic acid (CPA, 5 µmol/L) to deplete intracellular Ca2+
stores. Cells were then switched to the same solution supplemented with 1.8 mM CaCl2 to stimulate
TRPC-mediated Ca2+ entry. An increase in Fluo-4 fluorescence intensity following external Ca2+ rise
was measured and compared to baseline fluorescence. Ang (100 nM), Irb (1 µM), PD123319 (1 µM),
or the TRPC channel inhibitor SKF96365 (5 µM) were diluted in Tyrode’s solution containing CPA
with or without 1.8 mmol/L CaCl2. All reagents, unless otherwise specified, were purchases from
Sigma-Aldrich (Schnelldorf, Germany).
4.7. Solutions
Transport solution (mmol/L): KH2PO4 50, MgSO4 8, HEPES 10, adenosine 5, glucose 140, mannitol
100, and taurine 10 (pH 7.4 with KOH).
Tyrode’s solution (mmol/L): NaCl 132, KCl 4, MgCl2 1.2, HEPES 10, and glucose 11 (pH 7.35 with
NaOH). All reagents were purchases from Sigma-Aldrich (Schnelldorf, Germany).
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4.8. Statistical Analysis
All data are expressed as mean ± SEM. Statistical analysis was performed by one-way ANOVA
followed by post-hoc analysis or unpaired Student’s t-test when appropriate. A p-value of <0.05 was
taken to indicate statistical significance.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/19/
4912/s1.
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AT2R Ang type-2 receptor
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